These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of recombinant super-compound interferon (rSIFN-co) on human breast cancer cells in vitro].
    Author: Zheng J, Lü Q, Wei DP.
    Journal: Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 41(1):29-34, 48. PubMed ID: 20369465.
    Abstract:
    OBJECTIVE: To study the anti-cancer activities of recombinant super-compound interferon (rSIFN-co) against human breast cancer cells, its cooperative anti-tumor effect with chemotherapy and the possible mechanism of these effects. METHODS: The rSIFN-co, infergen, epirubicin were applied separately or combined in cultured human breast cancer cells MCF-7 and adriamycin-resistant strains of MCF-7/ADR cells. MTT assays and flow cytometry were applied to determine the growth inhibition and cell apoptosis index (AI) of MCF-7 and MCF-7/ ADR after different treatment. Immunohistochemical was used to detect the expression of P53, Bcl-2, CerbB-2 in treated MCF-7 and MCF-7/ADR cells. RESULTS: The rSIFN-co demonstrated a efficiency of inhibiting the cell proliferation, induce apoptosis of both MCF-7 cells and MCF-7/ADR cells, which was stronger than that of infergen in the same concentration; rSIFN-co combined with epirubicin has a synergistic action in inhibiting cell proliferation, inducing apoptosis of both type of breast cancer cells; rSIFN-co can also decrease the expression level of P53 and CerbB-2, increase the expression of Bcl-2 in both cell lines. CONCLUSION: In vitro conditions, rSIFN-co can inhibit cell growth of human breast cancer cell MCF-7 and MCF-7/ADR, which may attribute to influence the proliferation-associated factor expression, and induce apoptosis of cancer cells.
    [Abstract] [Full Text] [Related] [New Search]